Literature DB >> 26908434

Prospective Study of Human Polyomaviruses and Risk of Cutaneous Squamous Cell Carcinoma in the United States.

Anala Gossai1, Tim Waterboer2, Heather H Nelson3, Jennifer A Doherty4, Angelika Michel2, Martina Willhauck-Fleckenstein2, Shohreh F Farzan5, Brock C Christensen6, Anne G Hoen7, Ann E Perry8, Michael Pawlita2, Margaret R Karagas9.   

Abstract

BACKGROUND: Merkel cell polyomavirus (PyV) is causally related to Merkel cell carcinoma, a rare skin malignancy. Little is known about the serostability of other PyVs over time or associations with cutaneous squamous cell carcinoma (SCC).
METHODS: As part of a U.S. nested case-control study, antibody response against the PyV VP1 capsid proteins of BK and John Cunningham virus (JC) was measured using multiplex serology on 113 SCC cases and 229 gender, age, and study center-matched controls who had a prior keratinocyte cancer. Repeated serum samples from controls and both pre and postdiagnosis samples from a subset of SCC cases were also tested. Odds ratios (OR) for SCC associated with seropositivity to each PyV type were estimated using conditional logistic regression.
RESULTS: Among controls, BK and JC seroreactivity was stable over time, with intraclass correlation coefficients of 0.86 for BK and 0.94 for JC. Among cases, there was little evidence of seroconversion following SCC diagnosis. JC seropositivity prior to diagnosis was associated with an elevated risk of SCC (OR = 2.54; 95% CI, 1.23-5.25), and SCC risk increased with increasing quartiles of JC (Ptrend = 0.004) and BK (Ptrend = 0.02) seroreactivity.
CONCLUSIONS: PyV antibody levels were stable over time and following an SCC diagnosis. A history of PyV infection may be involved in the occurrence of SCC in a population at high risk for this malignancy. IMPACT: A single measure of PyV seroreactivity appears a reliable indicator of long-term antibody status, and PyV exposure may be a risk factor for subsequent SCC. Cancer Epidemiol Biomarkers Prev; 25(5); 736-44. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 26908434      PMCID: PMC4883679          DOI: 10.1158/1055-9965.EPI-15-1111

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  83 in total

1.  The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas.

Authors:  A De Luca; A Baldi; V Esposito; C M Howard; L Bagella; P Rizzo; M Caputi; H I Pass; G G Giordano; F Baldi; M Carbone; A Giordano
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

2.  A prospective longitudinal study of BK virus infection in 104 renal transplant recipients.

Authors:  C Bressollette-Bodin; M Coste-Burel; M Hourmant; V Sebille; E Andre-Garnier; B M Imbert-Marcille
Journal:  Am J Transplant       Date:  2005-08       Impact factor: 8.086

3.  New human papovavirus (B.K.) isolated from urine after renal transplantation.

Authors:  S D Gardner; A M Field; D V Coleman; B Hulme
Journal:  Lancet       Date:  1971-06-19       Impact factor: 79.321

4.  Latent BK virus infection and Kaposi's sarcoma pathogenesis.

Authors:  P Monini; A Rotola; L de Lellis; A Corallini; P Secchiero; A Albini; R Benelli; C Parravicini; G Barbanti-Brodano; E Cassai
Journal:  Int J Cancer       Date:  1996-06-11       Impact factor: 7.396

5.  Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.

Authors:  Margaret R Karagas; Heather H Nelson; Peter Sehr; Tim Waterboer; Therese A Stukel; Angeline Andrew; Adele C Green; Jan Nico Bouwes Bavinck; Ann Perry; Steven Spencer; Judy R Rees; Leila A Mott; Michael Pawlita
Journal:  J Natl Cancer Inst       Date:  2006-03-15       Impact factor: 13.506

6.  Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia.

Authors:  Tim Waterboer; Rachel Neale; Kristina M Michael; Peter Sehr; Maurits N C de Koning; Sönke J Weißenborn; Francesca Sampogna; Damiano Abeni; Adele C Green; Jan Nico Bouwes Bavinck; Michael Pawlita
Journal:  J Gen Virol       Date:  2009-04-22       Impact factor: 3.891

7.  Seroepidemiology of the human polyomaviruses.

Authors:  Annika Stolt; Kestutis Sasnauskas; Pentti Koskela; Matti Lehtinen; Joakim Dillner
Journal:  J Gen Virol       Date:  2003-06       Impact factor: 3.891

8.  Seroepidemiology of Human Polyomaviruses in a US Population.

Authors:  Anala Gossai; Tim Waterboer; Heather H Nelson; Angelika Michel; Martina Willhauck-Fleckenstein; Shohreh F Farzan; Anne G Hoen; Brock C Christensen; Karl T Kelsey; Carmen J Marsit; Michael Pawlita; Margaret R Karagas
Journal:  Am J Epidemiol       Date:  2015-12-13       Impact factor: 4.897

9.  High prevalence of antibodies against polyomavirus WU, polyomavirus KI, and human bocavirus in German blood donors.

Authors:  Florian Neske; Christiane Prifert; Barbara Scheiner; Moritz Ewald; Jörg Schubert; Andreas Opitz; Benedikt Weissbrich
Journal:  BMC Infect Dis       Date:  2010-07-20       Impact factor: 3.090

10.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden.

Authors:  J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  2 in total

1.  Early fulminant BK polyomavirus-associated nephropathy in two kidney transplant patients with low neutralizing antibody titers receiving allografts from the same donor.

Authors:  Elias Myrvoll Lorentzen; Stian Henriksen; Amandeep Kaur; Grete Birkeland Kro; Clara Hammarström; Hans H Hirsch; Karsten Midtvedt; Christine Hanssen Rinaldo
Journal:  Virol J       Date:  2020-01-10       Impact factor: 4.099

2.  Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank.

Authors:  Alexander J Mentzer; Nicole Brenner; Naomi Allen; Thomas J Littlejohns; Amanda Y Chong; Adrian Cortes; Rachael Almond; Michael Hill; Simon Sheard; Gil McVean; Rory Collins; Adrian V S Hill; Tim Waterboer
Journal:  Nat Commun       Date:  2022-04-05       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.